Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Преимущества кандесартана в лечении артериальной гипертонии
Преимущества кандесартана в лечении артериальной гипертонии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассмотрены особенности фармакокинетики блокаторов рецепторов ангиотензина II. Приведены данные об отличительных особенностях фармакокинетики и фармакодинамики кандесартана. Показана клиническая эффективность кандесартана в лечении артериальной гипертонии и снижении риска ее осложнений.
Ключевые слова: артериальная гипертония, кандесартан, суточное мониторирование артериального давления.
Key words: arterial hypertension, candesartan, 24-hour blood pressure monitoring.
Ключевые слова: артериальная гипертония, кандесартан, суточное мониторирование артериального давления.
________________________________________________
Key words: arterial hypertension, candesartan, 24-hour blood pressure monitoring.
Полный текст
Список литературы
1. Клиническая фармакология. Под ред. акад. РАН, проф. В.Г.Кукеса. Изд. 4-е. Москва: ГЭОТАР-Медиа, 2008; с. 392–6.
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4 редакция. Системные гипертензии. 2010; 3: 5–26.
3. Vanderheyden et al. Br J Pharmacol 1999; 126: 1057–65.
4. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension of the European Society of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31 (7): 1281–357.
5. Кобалава Ж.Д., Склизкова Л.А., Тарапата Н.П. Обоснование, опыт и перспективны применения кандесартана цилексетила. Клин. фармакология и терапия. 2001; 1: 92–6.
6. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
7. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
8. Imbs JL, Nisse-Durgeat S. French Collaborative Candesartan Study Group Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract 2005; 59: 78–84.
9. Malmgvist K. Am J Med 2000; 13: 504–5.
10. Gradman AH, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52–7.
11. Zhenfeng Zheng, Huilan Shi, Junya Jia et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12 (3): 365–74.
12. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16–21.
13. Vidt DG, White WB, Ridley E et al. and the CLAIM Study investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
14. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
15. Elliott HL. 24-hour control of cardiovascular disease. London: Science Press, 1995; p. 48.
16. Hansson L, Hedner T. Hypertension Manual 2000. –ayout Bohlin Production AB, 2000.
17. Kario K. Early morning risk management in hypertension. London: Science press, 2004; p. 3–11.
18. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107 (10): 1401–6.
19. Sakima A, Takishita S. Therapeutic strategy for morning blood pressure elevation in elderly hypertensives. Nihon Rinsho 2005; 6: 1086–90.
20. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (Suppl. 1): 29–37.
21. Weisser B, Gerwe M, Braun M, Funken C. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung 2005; 55 (9): 505–13.
22. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации, 4 редакция. Системные гипертензии. 2010; 3: 5–26.
3. Vanderheyden et al. Br J Pharmacol 1999; 126: 1057–65.
4. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension of the European Society of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2013; 31 (7): 1281–357.
5. Кобалава Ж.Д., Склизкова Л.А., Тарапата Н.П. Обоснование, опыт и перспективны применения кандесартана цилексетила. Клин. фармакология и терапия. 2001; 1: 92–6.
6. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
7. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
8. Imbs JL, Nisse-Durgeat S. French Collaborative Candesartan Study Group Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract 2005; 59: 78–84.
9. Malmgvist K. Am J Med 2000; 13: 504–5.
10. Gradman AH, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52–7.
11. Zhenfeng Zheng, Huilan Shi, Junya Jia et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12 (3): 365–74.
12. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16–21.
13. Vidt DG, White WB, Ridley E et al. and the CLAIM Study investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
14. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
15. Elliott HL. 24-hour control of cardiovascular disease. London: Science Press, 1995; p. 48.
16. Hansson L, Hedner T. Hypertension Manual 2000. –ayout Bohlin Production AB, 2000.
17. Kario K. Early morning risk management in hypertension. London: Science press, 2004; p. 3–11.
18. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107 (10): 1401–6.
19. Sakima A, Takishita S. Therapeutic strategy for morning blood pressure elevation in elderly hypertensives. Nihon Rinsho 2005; 6: 1086–90.
20. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (Suppl. 1): 29–37.
21. Weisser B, Gerwe M, Braun M, Funken C. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung 2005; 55 (9): 505–13.
22. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
Авторы
О.Д.Остроумова*1,2, О.В.Бондарец2, Т.Ф.Гусева2
1 Кафедра клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
2 Кафедра факультетской терапии и профессиональных болезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
*ostroumova.olga@mail.ru
*ostroumova.olga@mail.ru
1 Кафедра клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
2 Кафедра факультетской терапии и профессиональных болезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России
*ostroumova.olga@mail.ru
________________________________________________
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.